APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Vaccines Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchCancer Vaccines Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Vaccines Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Cancer Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Vaccines Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Vaccines Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Cancer Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Vaccines market include Merck, Pfizer, Glaxosmithkline, Serum Institute of India, Sanpower Group, Sanofi Pasteur, CSL Limited and Astellas Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Vaccines Segment by Company

Merck

Pfizer

Glaxosmithkline

Serum Institute of India

Sanpower Group

Sanofi Pasteur

CSL Limited

Astellas Pharma

Cancer Vaccines Segment by Type

Preventive Cancer Vaccines

Therapeutic Cancer Vaccines

Cancer Vaccines Segment by Application

Cervical Cancer

Prostate Cancer

Others

Cancer Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cancer Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cancer Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Vaccines industry.

Chapter 3: Detailed analysis of Cancer Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cancer Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cancer Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Vaccines Industry Trends Table 2. Cancer Vaccines Industry Drivers Table 3. Cancer Vaccines Industry Opportunities and Challenges Table 4. Cancer Vaccines Industry Restraints Table 5. Global Cancer Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Vaccines Revenue Share by Company (2021-2026) Table 7. Global Cancer Vaccines Sales Volume by Company (k units) & (2021-2026) Table 8. Global Cancer Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Cancer Vaccines Average Price (US$/unit) of Company (2021-2026) Table 10. Global Cancer Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cancer Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Cancer Vaccines Company, Product Type & Application Table 13. Global Cancer Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Preventive Cancer Vaccines Table 18. Significant Companies of Therapeutic Cancer Vaccines Table 19. Global Cancer Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Cancer Vaccines Sales Volume by Type (2021-2026) & (k units) Table 21. Global Cancer Vaccines Sales Volume by Type (2027-2032) & (k units) Table 22. Global Cancer Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Cancer Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Cancer Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cancer Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Cancer Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Cancer Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Cancer Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Cervical Cancer Table 30. Significant Companies of Prostate Cancer Table 31. Significant Companies of Others Table 32. Global Cancer Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Cancer Vaccines Sales Volume by Application (2021-2026) & (k units) Table 34. Global Cancer Vaccines Sales Volume by Application (2027-2032) & (k units) Table 35. Global Cancer Vaccines Sales Volume Share by Application (2021-2026) Table 36. Global Cancer Vaccines Sales Volume Share by Application (2027-2032) Table 37. Global Cancer Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Cancer Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Cancer Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Cancer Vaccines Sales Value Share by Application (2021-2026) Table 41. Global Cancer Vaccines Sales Value Share by Application (2027-2032) Table 42. Global Cancer Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Cancer Vaccines Sales by Region (2021-2026) & (k units) Table 44. Global Cancer Vaccines Sales Market Share by Region (2021-2026) Table 45. Global Cancer Vaccines Sales by Region (2027-2032) & (k units) Table 46. Global Cancer Vaccines Sales Market Share by Region (2027-2032) Table 47. Global Cancer Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Cancer Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Cancer Vaccines Sales Value Share by Region (2021-2026) Table 50. Global Cancer Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Cancer Vaccines Sales Value Share by Region (2027-2032) Table 52. Global Cancer Vaccines Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Cancer Vaccines Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Cancer Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Cancer Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Cancer Vaccines Sales by Country (2021-2026) & (k units) Table 57. Global Cancer Vaccines Sales Market Share by Country (2021-2026) Table 58. Global Cancer Vaccines Sales by Country (2027-2032) & (k units) Table 59. Global Cancer Vaccines Sales Market Share by Country (2027-2032) Table 60. Global Cancer Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Cancer Vaccines Sales Value Market Share by Country (2021-2026) Table 62. Global Cancer Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Cancer Vaccines Sales Value Market Share by Country (2027-2032) Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Cancer Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Merck Cancer Vaccines Product Portfolio Table 68. Merck Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Cancer Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Pfizer Cancer Vaccines Product Portfolio Table 73. Pfizer Recent Development Table 74. Glaxosmithkline Company Information Table 75. Glaxosmithkline Business Overview Table 76. Glaxosmithkline Cancer Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Glaxosmithkline Cancer Vaccines Product Portfolio Table 78. Glaxosmithkline Recent Development Table 79. Serum Institute of India Company Information Table 80. Serum Institute of India Business Overview Table 81. Serum Institute of India Cancer Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Serum Institute of India Cancer Vaccines Product Portfolio Table 83. Serum Institute of India Recent Development Table 84. Sanpower Group Company Information Table 85. Sanpower Group Business Overview Table 86. Sanpower Group Cancer Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Sanpower Group Cancer Vaccines Product Portfolio Table 88. Sanpower Group Recent Development Table 89. Sanofi Pasteur Company Information Table 90. Sanofi Pasteur Business Overview Table 91. Sanofi Pasteur Cancer Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Sanofi Pasteur Cancer Vaccines Product Portfolio Table 93. Sanofi Pasteur Recent Development Table 94. CSL Limited Company Information Table 95. CSL Limited Business Overview Table 96. CSL Limited Cancer Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. CSL Limited Cancer Vaccines Product Portfolio Table 98. CSL Limited Recent Development Table 99. Astellas Pharma Company Information Table 100. Astellas Pharma Business Overview Table 101. Astellas Pharma Cancer Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Astellas Pharma Cancer Vaccines Product Portfolio Table 103. Astellas Pharma Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Cancer Vaccines Distributors List Table 107. Cancer Vaccines Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Cancer Vaccines Product Image Figure 2. Global Cancer Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cancer Vaccines Sales (2021-2032) & (k units) Figure 5. Global Cancer Vaccines Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Cancer Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Preventive Cancer Vaccines Image Figure 10. Therapeutic Cancer Vaccines Image Figure 11. Global Cancer Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Cancer Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Cancer Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Cancer Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Cancer Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Cancer Vaccines Sales Value Share by Type (2021-2032) Figure 17. Cervical Cancer Image Figure 18. Prostate Cancer Image Figure 19. Others Image Figure 20. Global Cancer Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Cancer Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Cancer Vaccines Sales Volume Share by Application (2021-2032) Figure 23. Global Cancer Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Cancer Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Cancer Vaccines Sales Value Share by Application (2021-2032) Figure 26. Global Cancer Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Cancer Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Cancer Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Cancer Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 31. North America Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. South America Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Cancer Vaccines Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Cancer Vaccines Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines
Applications
  • Cervical Cancer
  • Prostate Cancer
  • Others
Companies covered
  • Merck
  • Pfizer
  • Glaxosmithkline
  • Serum Institute of India
  • Sanpower Group
  • Sanofi Pasteur
  • CSL Limited
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Cancer Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Cancer Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cancer Vaccines Market Dynamics
  1. 2.1 Cancer Vaccines Industry Trends
  2. 2.2 Cancer Vaccines Industry Drivers
  3. 2.3 Cancer Vaccines Industry Opportunities and Challenges
  4. 2.4 Cancer Vaccines Industry Restraints
3 Cancer Vaccines Market by Company
  1. 3.1 Global Cancer Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Cancer Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Cancer Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Cancer Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Cancer Vaccines Company Product Type and Application
  8. 3.8 Global Cancer Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cancer Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cancer Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cancer Vaccines Market by Type
  1. 4.1 Cancer Vaccines Type Introduction
  2. 4.1.1 Preventive Cancer Vaccines
  3. 4.1.2 Therapeutic Cancer Vaccines
  4. 4.2 Global Cancer Vaccines Sales Volume by Type
  5. 4.2.1 Global Cancer Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cancer Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Cancer Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Cancer Vaccines Sales Value by Type
  9. 4.3.1 Global Cancer Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Cancer Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Cancer Vaccines Sales Value Share by Type (2021-2032)
5 Cancer Vaccines Market by Application
  1. 5.1 Cancer Vaccines Application Introduction
  2. 5.1.1 Cervical Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Others
  5. 5.2 Global Cancer Vaccines Sales Volume by Application
  6. 5.2.1 Global Cancer Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Vaccines Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Cancer Vaccines Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Cancer Vaccines Sales Value by Application
  10. 5.3.1 Global Cancer Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Vaccines Sales Value by Application (2021-2032)
  12. 5.3.3 Global Cancer Vaccines Sales Value Share by Application (2021-2032)
6 Cancer Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Cancer Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Cancer Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Cancer Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cancer Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cancer Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cancer Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Cancer Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cancer Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cancer Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cancer Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cancer Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cancer Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
7 Cancer Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Cancer Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cancer Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Cancer Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Cancer Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Cancer Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cancer Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cancer Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cancer Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cancer Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cancer Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cancer Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cancer Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cancer Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cancer Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cancer Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cancer Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cancer Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cancer Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cancer Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cancer Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cancer Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cancer Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cancer Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cancer Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cancer Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cancer Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cancer Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cancer Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cancer Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cancer Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cancer Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cancer Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cancer Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cancer Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cancer Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Cancer Vaccines Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Cancer Vaccines Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Glaxosmithkline
  14. 8.3.1 Glaxosmithkline Company Information
  15. 8.3.2 Glaxosmithkline Business Overview
  16. 8.3.3 Glaxosmithkline Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Glaxosmithkline Cancer Vaccines Product Portfolio
  18. 8.3.5 Glaxosmithkline Recent Developments
  19. 8.4 Serum Institute of India
  20. 8.4.1 Serum Institute of India Company Information
  21. 8.4.2 Serum Institute of India Business Overview
  22. 8.4.3 Serum Institute of India Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Serum Institute of India Cancer Vaccines Product Portfolio
  24. 8.4.5 Serum Institute of India Recent Developments
  25. 8.5 Sanpower Group
  26. 8.5.1 Sanpower Group Company Information
  27. 8.5.2 Sanpower Group Business Overview
  28. 8.5.3 Sanpower Group Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanpower Group Cancer Vaccines Product Portfolio
  30. 8.5.5 Sanpower Group Recent Developments
  31. 8.6 Sanofi Pasteur
  32. 8.6.1 Sanofi Pasteur Company Information
  33. 8.6.2 Sanofi Pasteur Business Overview
  34. 8.6.3 Sanofi Pasteur Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur Cancer Vaccines Product Portfolio
  36. 8.6.5 Sanofi Pasteur Recent Developments
  37. 8.7 CSL Limited
  38. 8.7.1 CSL Limited Company Information
  39. 8.7.2 CSL Limited Business Overview
  40. 8.7.3 CSL Limited Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CSL Limited Cancer Vaccines Product Portfolio
  42. 8.7.5 CSL Limited Recent Developments
  43. 8.8 Astellas Pharma
  44. 8.8.1 Astellas Pharma Company Information
  45. 8.8.2 Astellas Pharma Business Overview
  46. 8.8.3 Astellas Pharma Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Astellas Pharma Cancer Vaccines Product Portfolio
  48. 8.8.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Vaccines Value Chain Analysis
  2. 9.1.1 Cancer Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Vaccines Sales Mode & Process
  6. 9.2 Cancer Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Vaccines Distributors
  9. 9.2.3 Cancer Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst